Oruka Therapeutics launches $500m public offering on Nasdaq
Oruka Therapeutics has launched a $500 million underwritten public offering of common stock, with pre-funded warrants available to certain investors in lieu of shares. The Menlo Park, California-based clinical-stage company has also granted underwriters a 30-day option to purchase a further $75 million of shares at the offering price, bringing the maximum gross proceeds to $575 million if the option is exercised in full.
Leerink Partners, TD Cowen, Goldman Sachs & Co., Stifel, and Guggenheim Securities are acting as joint bookrunning managers, with LifeSci Capital serving as passive bookrunner. The shelf registration statement underpinning the deal was declared effective by the Securities and Exchange Commission on 10 April 2026, and the offering is being made by means of a prospectus supplement filed with the SEC.
The deal
Oruka did not disclose in its announcement how the net proceeds will be deployed, which is unusual for a raise of this scale and is likely to draw questions from investors ahead of formal prospectus publication. The company is developing a portfolio of monoclonal antibodies targeting plaque psoriasis and related inflammatory indications, with the stated aim of achieving complete disease clearance on dosing schedules as infrequent as once or twice a year. Its antibody candidates were engineered by Paragon Therapeutics and are positioned by the company as potentially best-in-class in the indication.
The absence of a use-of-proceeds breakdown, combined with the lack of disclosed clinical stage or trial readout timelines in the release, limits the ability to assess how much runway this capital is intended to provide. Investors will look to the prospectus supplement for that detail, including any updates to the pipeline timeline.
Market context
The dermatology biologics space has become one of the most intensely contested arenas in immunology. Established agents targeting IL-17A, IL-23, and TNF pathways — including products from AbbVie, Janssen, Novartis, and Eli Lilly — have set a high bar for both efficacy and durability. A growing cohort of clinical-stage companies is pursuing extended-dosing schedules as a differentiating feature, reasoning that reduced injection frequency improves patient adherence and quality of life in a chronic condition that requires lifelong management.
Oruka's strategic emphasis on ultra-long dosing intervals places it alongside a small number of companies exploring half-life-extended antibody formats or subcutaneous depot technologies for dermatological indications. Whether that positioning proves commercially durable will depend heavily on the phase of data the company generates, the breadth of disease clearance achieved, and the safety profile over multi-year observation — none of which have been disclosed in available public materials.
A capital raise of this magnitude for a clinical-stage company signals meaningful institutional appetite, and the participation of top-tier banks in the bookrunning syndicate suggests demand has been tested ahead of the public announcement. However, biotech equity markets in 2026 have remained sensitive to macro interest-rate conditions, and the company's caveat that the offering remains subject to market conditions reflects genuine execution risk at this size.